Welcome to our dedicated page for HilleVax SEC filings (Ticker: HLVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to extract clinical trial milestones or cash-runway clues from a 200-page biotech filing? HilleVax’s SEC documents are packed with technical data on VLP vaccine research, partnership obligations, and milestone payments that can move the stock overnight.
Stock Titan translates that complexity into clarity. Our AI reads every HilleVax quarterly earnings report 10-Q filing, tags R&D spend trends, and explains risk-factor changes in plain English. Need real-time alerts? We stream HilleVax Form 4 insider transactions real-time so you never miss executive buys or sells. And when a surprise trial update hits, the platform posts a summary of the HilleVax 8-K material events explained within minutes.
Here’s what you can do on this page:
- Scan HilleVax annual report 10-K simplified to understand pipeline strategy without reading line-by-line.
- Dive into HilleVax proxy statement executive compensation to see how leadership incentives align with trial success.
- Monitor HilleVax insider trading Form 4 transactions and spot patterns ahead of catalysts.
- Get AI-driven HilleVax earnings report filing analysis that highlights liquidity and dilution risks.
Whether you’re understanding HilleVax SEC documents with AI for the first time or comparing quarters, our coverage spans every form—10-K, 10-Q, 8-K, S-3, and more. Stop searching Edgar; start focusing on decisions.
HilleVax, Inc. (HLVX) – Form 4 filing dated 06/25/2025
Non-employee director Patrick J. Heron reported the receipt of 17,199 Restricted Stock Units (RSUs) on 06/23/2025 at a cost basis of $0.00. The award was made under the company’s Non-Employee Director Compensation Program.
- Vesting: 100% on the earlier of (i) 06/23/2026 or (ii) a Change in Control, subject to continued board service.
- Post-transaction direct holdings: 17,199 shares.
- Indirect holdings: 8,535,337 shares held through Frazier Life Sciences X, L.P., for which Mr. Heron shares voting and investment control.
No derivative securities were reported. The filing represents routine director equity compensation rather than open-market activity and does not involve the sale or disposal of shares.
On June 23, 2025, HilleVax, Inc. (HLVX) director Julie L. Gerberding filed a Form 4 disclosing receipt of 17,199 Restricted Stock Units (RSUs) granted under the company’s Non-Employee Director Compensation Program. The award vests 100 % on the earlier of the first anniversary of the grant date or a defined Change in Control, contingent upon her continued board service. The RSUs were issued at $0.00 cost, indicating a non-cash, equity-based compensation item. Following the grant, Gerberding’s direct beneficial ownership rose to 59,224 common shares. No sales, option exercises, or other derivative transactions were reported.
HilleVax, Inc. (HLVX) – Form 4 filing dated 25-Jun-2025
Non-employee director Gary Dubin was granted 17,199 Restricted Stock Units (RSUs) on 23-Jun-2025 under HilleVax’s 2022 Incentive Award Plan and director compensation program. The RSUs were reported as an "A" (acquired) transaction at a cost basis of $0.00, increasing Dubin’s directly-held beneficial ownership to 17,199 common shares. Vesting is single-tranche: 100% on the earlier of (i) the first anniversary of grant or (ii) a Change in Control, contingent on continued board service. No derivative securities, sales, or additional purchases were disclosed.
The transaction represents routine annual equity compensation rather than an open-market purchase and therefore has limited immediate valuation impact. However, the grant modestly aligns director incentives with shareholder value and signals no insider selling.
HilleVax, Inc. filed a Form 8-K to report the results of its 23 June 2025 Annual Meeting of Stockholders. Two routine governance items were presented:
- Election of three Class III directors – Robert Hershberg, Jeryl Hilleman and Aditya Kohli were each re-elected for three-year terms, receiving roughly 22.0-22.4 million votes for and 1.5-1.8 million votes withheld; 14.5 million broker non-votes were recorded.
- Ratification of auditor – Ernst & Young LLP was confirmed as the Company’s independent registered public accounting firm for fiscal 2025 with 38.24 million votes for, 0.13 million against and 8,105 abstentions.
No other business or financial information was disclosed. The filing indicates normal, uncontested corporate governance with shareholder support for both board composition and external audit appointment.
FAQ
What is the current stock price of HilleVax (HLVX)?
What is the market cap of HilleVax (HLVX)?
What is HilleVax, Inc. focused on?
What technology does HilleVax utilize in its vaccine development?
What clinical stage is HilleVax currently in?
How does HilleVax address safety and regulatory concerns?
Who is at risk for the condition that HilleVax targets?
What differentiates HilleVax’s approach from traditional vaccine methods?
How is HilleVax positioned within the biopharmaceutical industry?
What are the primary research areas of HilleVax?
